Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLG2065 vs Novo Nordisk semaglutide in type 2 diabetes (China, Phase III)
CTR20230841Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Qilu Pharmaceutical. Started Jul 2023; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20230841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230841.